MedTrace Logo

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

NCT02954406 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2022-02-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of TAK-659 when administered in combination with bendamustine, bendamustine + rituximab, gemcitabine, lenalidomide, or ibrutinib.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

DRUG

TAK-659

TAK-659 immediate release tablet

DRUG

Bendamustine

Bendamustine intravenous infusion

DRUG

Rituximab

Rituximab intravenous infusion

DRUG

Gemcitabine

Gemcitabine intravenous infusion

DRUG

Lenalidomide

Lenalidomide capsule

DRUG

Ibrutinib

Ibrutinib capsule

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-05
Primary Completion
2020-07-27
Completion
2020-07-27
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02954406 on ClinicalTrials.gov